Who Is the Messi of Cannabis M&A? Seth Yakatan on Curaleaf, Aurora and Vireo

Cannabis consolidation is accelerating, but Seth Yakatan doesn’t see all M&A strategies as equal.

The veteran dealmaker and cannabis industry advisor sees two executives making particularly aggressive moves: Curaleaf Executive Chairman Boris Jordan and Vireo Growth CEO John Mazarakis. Their strategies are very different, but Yakatan sees both pursuing a level of scale that most of the cannabis industry is not equipped to match.

In an interview with IgniteIt, Yakatan described Jordan’s proposed acquisition of Aurora Cannabis as a strategically logical attempt to pair Curaleaf’s international distribution infrastructure with large-scale production capable of serving increasingly demanding European medical markets.

Vireo, meanwhile, represents a different consolidation thesis: acquiring and assembling assets across the United States at a pace Yakatan said he has rarely encountered during his career in finance.

“Mazarakis is executing a precision strategy at a time when no one else has either the capability, the intellect, the bandwidth, the capital, or the nuts to be able to do it,” Yakatan said.

But in both cases, buying assets is only the beginning. Whether these strategies ultimately create shareholder value will depend on what happens after the deals close.

Why Yakatan Thinks Aurora Makes Sense for Curaleaf

Yakatan’s interpretation of Curaleaf’s pursuit of Aurora starts with the infrastructure Jordan has already built.

Curaleaf has spent years developing an international cannabis distribution network. Yakatan believes the missing piece is reliable cultivation and processing capacity capable of supplying that network, particularly as European medical cannabis standards become increasingly important.

“It’s very clear that if you’re an insider, he’s been looking for a solution to take advantage of the European market and the cultivation,” Yakatan said.

In his view, Aurora offers precisely the kind of asset Curaleaf has been searching for.

“I think Boris has done a masterful job in trying to create a narrative to get a business which he fully believes is accretive and takes care of a high-margin space that needs to be occupied in the context of powering his global supply chain,” Yakatan said.

Yakatan believes the industry is beginning to place greater value on facilities capable of growing and processing cannabis that meets EU-GMP requirements at scale. Curaleaf has distribution infrastructure in Europe, but that network needs dependable product.

“I think what they decided is we need a big fucking facility that is tip-to-tail EU-GMP, so we can pump it into that supply chain,” he said.

That could make Aurora more valuable inside Curaleaf than as an independent company.

Curaleaf Is Looking at Aurora Like a Private Equity Buyer

Yakatan also offered a straightforward explanation for how Jordan may be thinking about valuation.

Rather than looking only at Aurora’s current earnings, he believes Curaleaf could be calculating what the company would earn after eliminating costs and integrating production into Curaleaf’s existing infrastructure.

“I think he’s looking at it like a private equity guy,” Yakatan said. “I can get rid of 20, 25% of the cost. I can plug it into my network. It’s instantly accretive.”

That also provides a potential explanation for Curaleaf’s willingness to offer a substantial premium.

“He didn’t come up with a premium just like this,” Yakatan said, arguing that Curaleaf likely calculated the maximum acquisition price the combined company could support after anticipated efficiencies.

Aurora’s ownership structure may also matter.

Yakatan noted that the company does not appear to have a single dominant shareholder capable of immediately determining the outcome of a takeover battle. That allows Curaleaf to take its argument directly to a dispersed shareholder base.

But he does not expect an easy transaction.

“I feel like this deal has a long ride home, a long and bumpy ride home,” Yakatan said.

Would $4 Be Enough for Aurora Shareholders?

For Aurora shareholders, Yakatan said the decision ultimately depends partly on their cost basis and on the final composition of the offer.

Assuming an investor bought Aurora at or below the tender price, he views the proposed premium as meaningful.

“I can’t see why, if I’m a shareholder, unless I’m in at some crazy high number, why a 40% premium to today’s share price wouldn’t be enough?” he said.

But the cash-versus-stock composition matters because Aurora shareholders receiving Curaleaf equity would also have to decide how much Curaleaf risk they are willing to assume.

“I think if you’re a shareholder, you then have to assess how much relative Curaleaf risk do I want to underwrite or not,” Yakatan said.

The Deal Could Reprice Other Cultivation Assets

One of Yakatan’s more interesting conclusions extends beyond Curaleaf and Aurora.

If Curaleaf is willing to pay a premium to secure large-scale compliant cultivation, other companies controlling strategically valuable production assets could benefit from the implied valuation.

“I think what you also see is a repricing of the EU-GMP assets as a result of it, because there’s not a lot of them on the planet, and there’s not a lot of them on the planet at scale,” Yakatan said.

He specifically identified Village Farms as a company whose assets become more interesting under that thesis. “If I’m a Village Farm shareholder, I am cheering,” he said and noted that he advises another potential beneficiary, Glass House, owns shares in the company, and is an investor.

Vireo Is Running a Different Consolidation Playbook

If Curaleaf represents the international side of cannabis consolidation, Yakatan sees Vireo pursuing an unusually aggressive version of the U.S. strategy.

He was equally explicit about his relationship with Vireo, saying he is “conflicted and restricted” because of his involvement through the Glass House joint venture with the company.

Even with that qualification, Yakatan is strongly bullish on the strategy being pursued by Mazarakis.

He described the Vireo CEO primarily as an operator, pointing to his history of building businesses before entering cannabis and his subsequent creation of Chicago Atlantic.

Yakatan believes Mazarakis ultimately intends to build something far larger than today’s Vireo.

“I think he has a goal, which is he wants to control 25% of global cannabis at top line,” Yakatan said. “I think he’s out to build a seven to eight billion-dollar revenue company.”

“I spent nine years at a leveraged finance fund. All we did was fund LBOs every day, all day. I’ve never seen anyone consolidating as quickly as he is.”

Yakatan said that in May he predicted Vireo would become the largest U.S. MSO by the end of 2026. By August, he said, it had already become the largest by store count.

Buying Companies Is Not the Same as Integrating Them

Yakatan nevertheless identified a clear risk to the Vireo strategy.

“Does he have the capacity to integrate, and does he have the capacity to operate?” he asked.

Those questions, rather than acquisition volume alone, will ultimately determine how investors value Vireo and whether its shareholders benefit from the consolidation strategy.

That distinction also gets to the broader point Yakatan makes about cannabis M&A.

Major transactions require teams that can get complex deals across the finish line without losing sight of the business they will have to operate afterward.

Yakatan compared it to assembling an elite football team: having one exceptional executive isn’t necessarily sufficient.

Looking across the industry, he sees Curaleaf and Vireo as unusually well equipped for that environment.

“When you think about big-time M&A like that, you don’t just need a Messi,” Yakatan said. “You need a team around a Messi.”

For Yakatan, that may help explain why Jordan and Mazarakis are moving while much of the rest of the industry remains on the sidelines.

Cannabis has spent years waiting for regulatory catalysts to determine which companies would emerge as the industry’s eventual winners. Curaleaf and Vireo are making a different bet: that companies can create their own catalysts through acquisitions, scale, and consolidation.

Whether those bets work will depend less on how many deals they can announce than on whether the businesses they assemble ultimately operate better together than they did apart.